TG Therapeutics, Inc.
TGTX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $616M | $329M | +87.3% |
| Operating income | $123M | $41.9M | +194% |
| Net income | $447M | $23.4M | +1,813% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $260M | $162M | +60.7% |
| Operating income | $85.9M | $29.4M | +192% |
| Net income | $55.5M | $391M | −85.8% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was TG Therapeutics's revenue in FY2025?
- $616M in FY2025 (Fiscal year ended Dec 31, 2025), +87.3% vs $329M a year earlier, per its 10-K filed Feb 2026.
- Was TG Therapeutics profitable in FY2025?
- Yes: net income was $447M and operating income $123M in FY2025.
- What was TG Therapeutics's revenue in Q3 2026?
- $260M (+60.7% vs a year earlier), per its Form 10-Q filed Nov 9, 2026.